SEC Comment Letter for Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581) — Jun 17, 2021
Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Date: June 17, 2021 · CIK: 0001792581 · Accession: 0000000000-21-007473
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo June 17, 2021 Maurizio Chiriva Internati, Ph.D. Chief Executive Officer Kiromic Biopharma, Inc. 7707 Fannin, Suite 140 Houston, TX 77054 Re:Kiromic Biopharma, Inc. Draft Registration Statement on Form S-1 Submitted June 11, 2021 CIK No. 0001792581 Dear Dr. Internati: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler, Esq.
Show Raw Text
United States securities and exchange commission logo
June 17, 2021
Maurizio Chiriva Internati, Ph.D.
Chief Executive Officer
Kiromic Biopharma, Inc.
7707 Fannin, Suite 140
Houston, TX 77054
Re:Kiromic Biopharma, Inc.
Draft Registration Statement on Form S-1
Submitted June 11, 2021
CIK No. 0001792581
Dear Dr. Internati:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Fessler, Esq.